PIKFYVE and cancer: The conclusion that cancer cells are significantly more sensitive to PIKFYVE inhibitors than normal cells has been confirmed in patient-derived cancer cells (ex vivo) and xenograft tumors derived from cancer cells (in vivo) (Table 3).